• 1
    Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: A literature review. Gen Hosp Psychiatry 2000; 22: 412424.
  • 2
    Ichimaru N, Kakuta Y, Abe T et al. Treatment adherence in renal transplant recipients: A questionnaire survey on immunosuppressants. Transplant Proc 2008; 40: 13621365.
  • 3
    Chisholm MA, Middleton MD. Modified-release tacrolimus. Ann Pharmacother 2006; 40: 270275.
  • 4
    Alloway R, Steinberg S, Khalil K et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867870.
  • 5
    Silva HT, Jr., Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595608.
  • 6
    Kramer BK, Charpentier B, Backman L et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 26322643.
  • 7
    Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920926.
  • 8
    Undre NA, van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296298.
  • 9
    Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: Twice daily versus once daily dosing. Am J Transplant 2004; 4: 621625.
  • 10
    Cross SA, Perry CM. Tacrolimus once-daily formulation: In the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs 2007; 67: 19311943.
  • 11
    Astellas. Advagraf -EMEA/H/C/000712 -IA/0016/G. Summary of product Characteristics (SmPC). In., 20/09/2010.
  • 12
    Alloway R, Steinberg S, Khalil K et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 16481651.
  • 13
    de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523529.
  • 14
    Hougardy JM, Broeders N, Kianda M et al. Conversion from prograf to advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566569.
  • 15
    Mecule A, Poli L, Nofroni I et al. Once daily tacrolimus formulation: Monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 2010; 42: 13171319.
  • 16
    Diez Ojea B, Alonso Alvarez M, Aguado Fernandez S, Banos Gallardo M, Garcia Melendreras S, Gomez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc 2009; 41: 23232325.
  • 17
    Crespo M, Mir M, Marin M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009; 41: 21152117.
  • 18
    Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176182.
  • 19
    Abecassis MM, Seifeldin R, Riordan ME. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: Results of a modeling analysis. Transplant Proc 2008; 40: 14431445.
  • 20
    Kurnatowska I, Banasiak M, Daniel P, Wagrowska-Danilewicz M, Nowicki M. Two cases of severe de novo colitis in kidney transplant recipients after conversion to prolonged-release tacrolimus. Transpl Int 2010; 23: 553558.
  • 21
    van Hooff J, Van Der Walt I, Kallmeyer J et al. Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen [abstract]. In: Proceedings of the 3rd International Congress on Immunosuppression; 2004 8th–11th December; San Diego, CA, USA; 2004. p. 53-abstr 26.
  • 22
    van Hooff J, Van Der Walt I, Kallmeyer J, Miller D, Dawood S, Moosa M. Two-year follow-up of stable kidney transplante recipients converted from twice daily Prograf to once daily modified release tacrolimus [abstract]. In: Proceedings of the 13th Congress of the European Society for Organ Transplantation (ESOT) and the 15th Congress of the European Transplant Coordinators Organization (ETCO); 2007 29th September–3rd October; Prague, Czech Republic; 2007. p. 129-abstr P141.
  • 23
    van Hooff JP, Alloway RR, Trunecka P, Mourad M. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant 2011; 25: E1E12.
  • 24
    Morales J, Lauzurica R, van Hooff J. Renal function and safety in stable kidney recipients converted from tacrolimus twice daily to once-daily formulation [abstract]. In: Proceedings of the American Transplant Congress; 2009 30th May–3rd June; Boston, MA, USA; 2009. p. 512-abstr 1138.
  • 25
    Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, Martinez-Fernandez G, Perez-Martinez J, Gomez-Roldan C. Conversion to tacrolimus extended-release formulation: Short-term clinical results. Transplant Proc 2009; 41: 23262327.